Acquired cutis laxa secondary to Sweet syndrome in a child (Marshall syndrome): A rare case report

J Cutan Pathol. 2020 Feb;47(2):146-149. doi: 10.1111/cup.13567. Epub 2019 Aug 30.

Abstract

Sweet syndrome is rare in the pediatric population and usually responds well to treatment, resolving without sequelae. Marshall syndrome is a rare pediatric skin disease characterized by loss of elastic tissue (cutis laxa) secondary to acquired, localized neutrophilic dermatitis without any internal organ involvement. Only few cases of Marshall syndrome (acquired cutis laxa type II) have been reported. Systemic steroids and dapsone show excellent results in Sweet syndrome. Although there is no satisfactory treatment for cutis laxa, dapsone can be used in the acute phase for control of swelling.

Keywords: Cutis laxa; Marshall syndrome; Sweet syndrome.

Publication types

  • Case Reports

MeSH terms

  • Cataract / drug therapy*
  • Cataract / metabolism
  • Cataract / pathology
  • Child, Preschool
  • Collagen Type XI / deficiency*
  • Collagen Type XI / metabolism
  • Craniofacial Abnormalities / drug therapy*
  • Craniofacial Abnormalities / metabolism
  • Craniofacial Abnormalities / pathology
  • Cutis Laxa* / drug therapy
  • Cutis Laxa* / metabolism
  • Cutis Laxa* / pathology
  • Dapsone / administration & dosage*
  • Female
  • Hearing Loss, Sensorineural / drug therapy*
  • Hearing Loss, Sensorineural / metabolism
  • Hearing Loss, Sensorineural / pathology
  • Humans
  • Osteochondrodysplasias / drug therapy*
  • Osteochondrodysplasias / metabolism
  • Osteochondrodysplasias / pathology
  • Sweet Syndrome* / drug therapy
  • Sweet Syndrome* / metabolism
  • Sweet Syndrome* / pathology

Substances

  • Collagen Type XI
  • Dapsone

Supplementary concepts

  • Marshall syndrome